Association of medical insurance and other factors with receipt of antiretroviral therapy

Jeanne C Keruly, Richard Conviser, Richard D Moore

Research output: Contribution to journalArticle

Abstract

Objectives, This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART). Methods, Patients included (n=959) were enrolled in the Johns Hopkins HIV Clinic after April 1, 1996, received ≥90 days of care, and had a CD4 count ≥500 cells/mm3 or HIV-1 RNA > 20 000 copies/mL. We assessed the associations of sociodemographic factors and medical insurance with receipt of HAART, stratified by 2 time periods (April 1996 through March 1997 versus April 1997 through March 1999). Results. HAART was more likely to be used in patients who were >39 years, White, had CD4 counts 3, had fewer missed clinic visits, and did not have intravenous drug use as their risk factor for HIV transmission. In period 1 (April 1996 through March 1997), HAART was more likely to be used in patients who were commercially insured than in other payer groups; differences between payers narrowed in period 2 (April 1997 through March 1999), however, as did differences by race. Conclusions. Differences in use of HAART on the basis of payer have narrowed since 1996. This encouraging finding may demonstrate the importance of programs that lower economic barriers to medical care.

Original languageEnglish (US)
Pages (from-to)852-857
Number of pages6
JournalAmerican Journal of Public Health
Volume92
Issue number5
StatePublished - 2002

Fingerprint

Highly Active Antiretroviral Therapy
Insurance
CD4 Lymphocyte Count
HIV
Therapeutics
Insurance Carriers
Ambulatory Care
HIV-1
Economics
RNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Association of medical insurance and other factors with receipt of antiretroviral therapy. / Keruly, Jeanne C; Conviser, Richard; Moore, Richard D.

In: American Journal of Public Health, Vol. 92, No. 5, 2002, p. 852-857.

Research output: Contribution to journalArticle

@article{91a3fba10d6a459da7737fb251fac6f1,
title = "Association of medical insurance and other factors with receipt of antiretroviral therapy",
abstract = "Objectives, This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART). Methods, Patients included (n=959) were enrolled in the Johns Hopkins HIV Clinic after April 1, 1996, received ≥90 days of care, and had a CD4 count ≥500 cells/mm3 or HIV-1 RNA > 20 000 copies/mL. We assessed the associations of sociodemographic factors and medical insurance with receipt of HAART, stratified by 2 time periods (April 1996 through March 1997 versus April 1997 through March 1999). Results. HAART was more likely to be used in patients who were >39 years, White, had CD4 counts 3, had fewer missed clinic visits, and did not have intravenous drug use as their risk factor for HIV transmission. In period 1 (April 1996 through March 1997), HAART was more likely to be used in patients who were commercially insured than in other payer groups; differences between payers narrowed in period 2 (April 1997 through March 1999), however, as did differences by race. Conclusions. Differences in use of HAART on the basis of payer have narrowed since 1996. This encouraging finding may demonstrate the importance of programs that lower economic barriers to medical care.",
author = "Keruly, {Jeanne C} and Richard Conviser and Moore, {Richard D}",
year = "2002",
language = "English (US)",
volume = "92",
pages = "852--857",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "5",

}

TY - JOUR

T1 - Association of medical insurance and other factors with receipt of antiretroviral therapy

AU - Keruly, Jeanne C

AU - Conviser, Richard

AU - Moore, Richard D

PY - 2002

Y1 - 2002

N2 - Objectives, This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART). Methods, Patients included (n=959) were enrolled in the Johns Hopkins HIV Clinic after April 1, 1996, received ≥90 days of care, and had a CD4 count ≥500 cells/mm3 or HIV-1 RNA > 20 000 copies/mL. We assessed the associations of sociodemographic factors and medical insurance with receipt of HAART, stratified by 2 time periods (April 1996 through March 1997 versus April 1997 through March 1999). Results. HAART was more likely to be used in patients who were >39 years, White, had CD4 counts 3, had fewer missed clinic visits, and did not have intravenous drug use as their risk factor for HIV transmission. In period 1 (April 1996 through March 1997), HAART was more likely to be used in patients who were commercially insured than in other payer groups; differences between payers narrowed in period 2 (April 1997 through March 1999), however, as did differences by race. Conclusions. Differences in use of HAART on the basis of payer have narrowed since 1996. This encouraging finding may demonstrate the importance of programs that lower economic barriers to medical care.

AB - Objectives, This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART). Methods, Patients included (n=959) were enrolled in the Johns Hopkins HIV Clinic after April 1, 1996, received ≥90 days of care, and had a CD4 count ≥500 cells/mm3 or HIV-1 RNA > 20 000 copies/mL. We assessed the associations of sociodemographic factors and medical insurance with receipt of HAART, stratified by 2 time periods (April 1996 through March 1997 versus April 1997 through March 1999). Results. HAART was more likely to be used in patients who were >39 years, White, had CD4 counts 3, had fewer missed clinic visits, and did not have intravenous drug use as their risk factor for HIV transmission. In period 1 (April 1996 through March 1997), HAART was more likely to be used in patients who were commercially insured than in other payer groups; differences between payers narrowed in period 2 (April 1997 through March 1999), however, as did differences by race. Conclusions. Differences in use of HAART on the basis of payer have narrowed since 1996. This encouraging finding may demonstrate the importance of programs that lower economic barriers to medical care.

UR - http://www.scopus.com/inward/record.url?scp=0036236694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036236694&partnerID=8YFLogxK

M3 - Article

C2 - 11988459

AN - SCOPUS:0036236694

VL - 92

SP - 852

EP - 857

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 5

ER -